Eden Innovations Limited (ASX:EDE) — How Did US Sales and Concrete Plant Installations Develop?

Aditi Sarkar

04 November 2026 06:40 PM AEDT

Eden Innovations Limited (ASX:EDE) — How Did US Sales and Concrete Plant Installations Develop?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Eden Innovations Limited (ASX:EDE) reported on its 2026 operating activities, financial position and project developments. Its recent disclosures address EdenCrete and OptiBlend sales, bulk installations and the company’s cash position.
Its US Subsidiary recorded quarterly sales of USD 381,612, equivalent to AUD 549,521, more than two-and-a-half times the comparable prior-year period.
Eden installed six EdenCrete Pz7 bulk storage and dispensing systems at ready-mix plants in Colorado, Texas and Minnesota.
the company recorded US subsidiary sales of USD 381,612 in the September quarter, more than twice the prior-year level.
Six new EdenCrete Pz7 dispensing installations were completed in the United States; closing cash stood at AUD 4.3 million.

Eden Innovations Limited (ASX:EDE) develops and sells products used in concrete Manufacturing and dual-fuel engine applications, including EdenCrete and OptiBlend. Its shares were quoted at AUD 0.053, down 1.85%, on 4 November 2026. Commercial activity during the September quarter included US product sales, new concrete-plant installations and work to expand distribution across multiple markets.

The quarterly activities report released on 30 October 2026 detailed US subsidiary sales of USD 381,612 and six new EdenCrete Pz7 dispensing installations. The company also reported AUD 4.3 million in cash at 30 September 2026 and the settlement of outstanding Shareholder loans and accrued director fees through Equity issues.

Projects and Operating Milestones

Its US subsidiary recorded quarterly sales of USD 381,612, equivalent to AUD 549,521, more than two-and-a-half times the comparable prior-year period. OptiBlend sales totalled USD 259,863, representing 247% year-on-year growth, while EdenCrete product sales totalled USD 121,749, 60% higher than a year earlier. the company received nine OptiBlend orders during the period and submitted 16 additional US quotations valued at approximately USD 916,000. Quoted work has not been included in actual quarterly sales. The report also described an initial export sale of OptiBlend equipment to Brazil.

Reported Financial and Corporate Figures

Eden installed six EdenCrete Pz7 bulk storage and dispensing systems at ready-mix plants in Colorado, Texas and Minnesota. Two further US installations were scheduled for October. Along with operating sites in Canada and Ecuador, the company reported a network of 32 installed or scheduled facilities on the basis stated in the quarterly report. Eden also described concrete projects using its additive, including residential construction and hospital work in Colorado. The growth of installation locations and the conversion of installed sites into recurring product purchases remain distinct measures of its commercial activity.

Technical Programme and Outstanding Work

Indian testing of EdenCrete was another area of work. A report from the Central Road Research Institute identified improvements in selected concrete characteristics relative to control mixes, including abrasion resistance, compressive strength, flexural strength and reduced drying shrinkage. Eden India planned to explore accelerated field trials and maintained a commercial focus on ready-mix customers in Mumbai and Delhi. Following shareholder approval in July 2026, the company settled remaining shareholder loans and accrued director fees through shares. This was the basis for Eden’s reported debt-free position at the end of September.

the company described further sales opportunities separately from completed transactions. Orders and quotations for customers in South America were under discussion, while the first Brazilian OptiBlend export sale had already taken place. Eden stated that starter quantities associated with a newly installed concrete-dispensing system can differ from the subsequent recurring consumption of additives. Its concrete product installations therefore indicate distribution capacity, not guaranteed annual sales from each facility. The Indian laboratory work also remains distinct from road-contract awards or widespread product deployment. Each of these stages was treated separately within the September 2026 operational record.

Key Insights

the company reported a combination of completed 2026 activity and work scheduled for later periods. Its disclosed figures distinguish reported operating results or cash balances from targets, estimates and proposed arrangements. The principal developments covered here relate to us concrete additives expansion and optiblend sales. Future programs remain subject to the specific approvals, financing, commercial terms or technical results identified in the company’s disclosures. The share-price Quotation presented above is a historical reference and is not described as a verified live quote for 4 November 2026.

FAQs

Q: What were US quarterly sales?

A: USD 381,612.

Q: How much did OptiBlend sales grow?

A: 247% year on year.

Q: How many new US systems were installed?

A: Six during the September quarter.

Q: What was quarter-end cash?

A: AUD 4.3 million.

Q: What did Indian testing examine?

A: Strength, abrasion and drying-shrinkage performance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.